Global pharmaceutical company Allergan has announced it will purchase clinical-stage biotechnology company Vitae Pharmaceuticals.
The acquisition will allow Allergan to have access to new dermatology advances, including VTP-43742, an orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders.
The deal will also add VTP-38543 to Allergan’s offering. It is a topical LXRβ (Liver X Receptor beta) selective agonist for the potential treatment of atopic dermatitis and works by decreasing inflammation in damaged skin tissue and repairing the damaged outer layer of skin.
“The acquisition of Vitae is a strategic investment for Allergan that adds strength and depth to our innovative medical dermatology franchise,” said Brent Saunders, CEO and president of Allergan. “Vitae has pioneered the discovery and development of highly differentiated first-in-class compounds in atopic dermatitis, psoriasis and autoimmune diseases, areas of medicine where innovation is needed for patients,” he added.